![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and Efficacy of Inhaled Interferon-β1a
(SNG001) in a Phase II Randomized Controlled Trial of Adults with Mild-to-Moderate COVID-19
|
|
|
CROI 2023 Feb 20-23
William A. Fischer II, MD
On Behalf of the ACTIV-2/A5401 Team
Associate Professor of Medicine
Director of Emerging Pathogens
Division of Pulmonary and Critical Care Medicine
The University of North Carolina at Chapel Hill
![0314231](../images/031423/031423-10/0314231.gif)
![0314232](../images/031423/031423-10/0314232.gif)
![0314233](../images/031423/031423-10/0314233.gif)
![0314234](../images/031423/031423-10/0314234.gif)
![0314235](../images/031423/031423-10/0314235.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|